Harrow Health to Announce Q4 Earnings on March 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy HROW?
Source: seekingalpha
- Earnings Announcement Date: Harrow Health is set to release its Q4 2023 earnings report on March 2 after market close, with a consensus EPS estimate of $0.47, reflecting a 17.5% year-over-year growth that underscores the company's ongoing potential in the eyecare sector.
- Revenue Expectations: The anticipated revenue for Q4 is $88.42 million, representing a robust 32.3% year-over-year increase, indicating the company's competitive position and rising product demand in the market.
- Historical Performance Review: Over the past two years, Harrow Health has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, showcasing a degree of volatility in financial performance that could impact investor confidence.
- Market Focus: As the earnings report approaches, market attention on Harrow Health intensifies, particularly as the company navigates challenges related to its revised guidance for 2025, with investors keenly watching whether the upcoming results can support future growth expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HROW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HROW
Wall Street analysts forecast HROW stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 53.990
Low
63.00
Averages
72.40
High
94.00
Current: 53.990
Low
63.00
Averages
72.40
High
94.00
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harrow Health to Announce Q4 Earnings on March 2
- Earnings Announcement Date: Harrow Health is set to release its Q4 2023 earnings report on March 2 after market close, with a consensus EPS estimate of $0.47, reflecting a 17.5% year-over-year growth that underscores the company's ongoing potential in the eyecare sector.
- Revenue Expectations: The anticipated revenue for Q4 is $88.42 million, representing a robust 32.3% year-over-year increase, indicating the company's competitive position and rising product demand in the market.
- Historical Performance Review: Over the past two years, Harrow Health has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, showcasing a degree of volatility in financial performance that could impact investor confidence.
- Market Focus: As the earnings report approaches, market attention on Harrow Health intensifies, particularly as the company navigates challenges related to its revised guidance for 2025, with investors keenly watching whether the upcoming results can support future growth expectations.
See More
OSRX Continues Support for California Ophthalmologists After Competitor's Exit
- Market Response: Following the voluntary license forfeiture by competitor ImprimisRx, OSRX remains fully operational, ensuring that the needs of California ophthalmologists and optometrists are met, demonstrating its stability and reliability in the market.
- Compliance and Fines: ImprimisRx's settlement with the California Board of Pharmacy, which includes a $157,000 fine, highlights the strict regulatory environment, while OSRX maintains compliance across all 50 states, enhancing its market credibility.
- Service Commitment: OSRX emphasizes its FDA-registered 503B outsourcing facility's provision of high-quality compounded ophthalmic medications, supporting both direct-to-patient and direct-to-facility dispensing models, ensuring California clinicians have uninterrupted access to necessary medications.
- Customer Support Network: Currently supporting over 10,000 prescribers, OSRX is dedicated to providing seamless medication supply solutions for ophthalmologists and optometrists nationwide, further solidifying its leadership position in ophthalmic care.
See More
OSRX Continues Support in California Market After Competitor Exit
- Market Shift: Following the voluntary forfeiture of its California license by competitor ImprimisRx, OSRX remains committed to supporting California ophthalmologists and optometrists, ensuring its operations in the state are unaffected, which highlights its stability and reliability in the industry.
- Compliance and Operations: As an FDA-registered 503B outsourcing facility, OSRX emphasizes its legal operations across all 50 states, ensuring the provision of high-quality compounded medications to meet the needs for post-operative care, glaucoma management, and myopia control.
- Customer Support Commitment: CEO Anthony Sampietro stated that OSRX supports over 10,000 prescribers nationwide, dedicated to providing uninterrupted access to high-quality compounded medications for California clinicians and their patients, thereby enhancing trust and reliance on their services.
- Easy Access for Prescribers: California prescribers can quickly onboard with OSRX by visiting their website or contacting the West Account Executive directly, further strengthening the company's competitive advantage and customer service capabilities in the market.
See More
Okta Inc (OKTA) Options Volume Hits 13,284 Contracts, 52.9% of Average Daily Volume
- Active Options Trading: Okta Inc's options volume today reached 13,284 contracts, equivalent to approximately 1.3 million shares, indicating robust activity in the options market, with this volume representing 52.9% of its average daily trading volume of 2.5 million shares over the past month.
- High Volume Insights: Notably, the $91 strike put option has seen significant trading, with 1,939 contracts exchanged today, representing about 193,900 underlying shares, reflecting market attention at this price level and potential risk management strategies.
- Harrow Inc Options Activity: Concurrently, Harrow Inc recorded an options volume of 3,058 contracts, equivalent to approximately 305,800 shares, which is about 52.6% of its average daily trading volume of 581,730 shares over the past month, indicating relative activity in its options market.
- Bullish Call Options Trend: The $55 strike call option for Harrow Inc also attracted attention, with a trading volume of 1,106 contracts today, representing around 110,600 underlying shares, suggesting investor optimism regarding the company's future performance.
See More
Antero Resources Sees 31,767 Options Contracts Trading, 64.9% of Average Volume
- Active Options Trading: Antero Resources Corp (AR) recorded an options trading volume of 31,767 contracts today, equating to approximately 3.2 million shares, which represents 64.9% of its average daily trading volume of 4.9 million shares over the past month, indicating a significant increase in market interest in the stock.
- Put Option Concentration: Notably, the $28 strike put option expiring on February 20, 2026, saw a trading volume of 23,642 contracts today, representing about 2.4 million underlying shares, reflecting heightened investor expectations for potential downward price movement in the future.
- Shift4 Payments Options Activity: Shift4 Payments Inc (FOUR) has seen an options trading volume of 9,949 contracts today, equivalent to approximately 994,900 shares, which also constitutes 64.9% of its average daily trading volume of 1.5 million shares over the past month, showcasing the stock's active market engagement.
- Call Option Trading: The $65 strike call option for FOUR recorded a trading volume of 4,127 contracts today, representing around 412,700 underlying shares, indicating increased investor confidence in the stock's potential for upward movement, which may influence its short-term price trajectory.
See More
Significant Friday Options Trading: HROW, EWTX, RBLX
EWTX Options Activity: Edgewise Therapeutics Inc (EWTX) has seen a trading volume of 6,697 options contracts today, equating to about 669,700 underlying shares, which is 55.2% of its average daily trading volume over the past month.
High Volume Call Option for EWTX: The $24 strike call option expiring on December 19, 2025, has particularly high activity with 3,385 contracts traded, representing approximately 338,500 underlying shares.
RBLX Options Activity: Roblox Corp (RBLX) has recorded a trading volume of 40,105 options contracts today, amounting to around 4.0 million underlying shares, which is 54.3% of its average daily trading volume over the past month.
High Volume Call Option for RBLX: The $105 strike call option expiring on January 16, 2026, has seen significant trading with 5,351 contracts, representing about 535,100 underlying shares.
See More
Harrow Health to Announce Q4 Earnings on March 2
- Earnings Announcement Date: Harrow Health is set to release its Q4 2023 earnings report on March 2 after market close, with a consensus EPS estimate of $0.47, reflecting a 17.5% year-over-year growth that underscores the company's ongoing potential in the eyecare sector.
- Revenue Expectations: The anticipated revenue for Q4 is $88.42 million, representing a robust 32.3% year-over-year increase, indicating the company's competitive position and rising product demand in the market.
- Historical Performance Review: Over the past two years, Harrow Health has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, showcasing a degree of volatility in financial performance that could impact investor confidence.
- Market Focus: As the earnings report approaches, market attention on Harrow Health intensifies, particularly as the company navigates challenges related to its revised guidance for 2025, with investors keenly watching whether the upcoming results can support future growth expectations.
See More
OSRX Continues Support for California Ophthalmologists After Competitor's Exit
- Market Response: Following the voluntary license forfeiture by competitor ImprimisRx, OSRX remains fully operational, ensuring that the needs of California ophthalmologists and optometrists are met, demonstrating its stability and reliability in the market.
- Compliance and Fines: ImprimisRx's settlement with the California Board of Pharmacy, which includes a $157,000 fine, highlights the strict regulatory environment, while OSRX maintains compliance across all 50 states, enhancing its market credibility.
- Service Commitment: OSRX emphasizes its FDA-registered 503B outsourcing facility's provision of high-quality compounded ophthalmic medications, supporting both direct-to-patient and direct-to-facility dispensing models, ensuring California clinicians have uninterrupted access to necessary medications.
- Customer Support Network: Currently supporting over 10,000 prescribers, OSRX is dedicated to providing seamless medication supply solutions for ophthalmologists and optometrists nationwide, further solidifying its leadership position in ophthalmic care.
See More
OSRX Continues Support in California Market After Competitor Exit
- Market Shift: Following the voluntary forfeiture of its California license by competitor ImprimisRx, OSRX remains committed to supporting California ophthalmologists and optometrists, ensuring its operations in the state are unaffected, which highlights its stability and reliability in the industry.
- Compliance and Operations: As an FDA-registered 503B outsourcing facility, OSRX emphasizes its legal operations across all 50 states, ensuring the provision of high-quality compounded medications to meet the needs for post-operative care, glaucoma management, and myopia control.
- Customer Support Commitment: CEO Anthony Sampietro stated that OSRX supports over 10,000 prescribers nationwide, dedicated to providing uninterrupted access to high-quality compounded medications for California clinicians and their patients, thereby enhancing trust and reliance on their services.
- Easy Access for Prescribers: California prescribers can quickly onboard with OSRX by visiting their website or contacting the West Account Executive directly, further strengthening the company's competitive advantage and customer service capabilities in the market.
See More
Okta Inc (OKTA) Options Volume Hits 13,284 Contracts, 52.9% of Average Daily Volume
- Active Options Trading: Okta Inc's options volume today reached 13,284 contracts, equivalent to approximately 1.3 million shares, indicating robust activity in the options market, with this volume representing 52.9% of its average daily trading volume of 2.5 million shares over the past month.
- High Volume Insights: Notably, the $91 strike put option has seen significant trading, with 1,939 contracts exchanged today, representing about 193,900 underlying shares, reflecting market attention at this price level and potential risk management strategies.
- Harrow Inc Options Activity: Concurrently, Harrow Inc recorded an options volume of 3,058 contracts, equivalent to approximately 305,800 shares, which is about 52.6% of its average daily trading volume of 581,730 shares over the past month, indicating relative activity in its options market.
- Bullish Call Options Trend: The $55 strike call option for Harrow Inc also attracted attention, with a trading volume of 1,106 contracts today, representing around 110,600 underlying shares, suggesting investor optimism regarding the company's future performance.
See More
Antero Resources Sees 31,767 Options Contracts Trading, 64.9% of Average Volume
- Active Options Trading: Antero Resources Corp (AR) recorded an options trading volume of 31,767 contracts today, equating to approximately 3.2 million shares, which represents 64.9% of its average daily trading volume of 4.9 million shares over the past month, indicating a significant increase in market interest in the stock.
- Put Option Concentration: Notably, the $28 strike put option expiring on February 20, 2026, saw a trading volume of 23,642 contracts today, representing about 2.4 million underlying shares, reflecting heightened investor expectations for potential downward price movement in the future.
- Shift4 Payments Options Activity: Shift4 Payments Inc (FOUR) has seen an options trading volume of 9,949 contracts today, equivalent to approximately 994,900 shares, which also constitutes 64.9% of its average daily trading volume of 1.5 million shares over the past month, showcasing the stock's active market engagement.
- Call Option Trading: The $65 strike call option for FOUR recorded a trading volume of 4,127 contracts today, representing around 412,700 underlying shares, indicating increased investor confidence in the stock's potential for upward movement, which may influence its short-term price trajectory.
See More
Significant Friday Options Trading: HROW, EWTX, RBLX
EWTX Options Activity: Edgewise Therapeutics Inc (EWTX) has seen a trading volume of 6,697 options contracts today, equating to about 669,700 underlying shares, which is 55.2% of its average daily trading volume over the past month.
High Volume Call Option for EWTX: The $24 strike call option expiring on December 19, 2025, has particularly high activity with 3,385 contracts traded, representing approximately 338,500 underlying shares.
RBLX Options Activity: Roblox Corp (RBLX) has recorded a trading volume of 40,105 options contracts today, amounting to around 4.0 million underlying shares, which is 54.3% of its average daily trading volume over the past month.
High Volume Call Option for RBLX: The $105 strike call option expiring on January 16, 2026, has seen significant trading with 5,351 contracts, representing about 535,100 underlying shares.
See More
